- Other Post Graduate Training - Massachusetts Institute of Technology (2004-2010)
- Graduate School - Massachusetts Institute of Technology (2004-2010)
- Medical School - Rutgers New Jersey Medical School (2011-2014)
- Internship - UT Southwestern Medical Center (2014-2015)
- Residency - UT Southwestern Medical Center (2014-2016), Internal Medicine
- Fellowship - Massachusetts General Hospital (2016-2020), Gastroenterology
Suraj Patel, M.D., Ph.D.
- Internal Medicine - Digestive and Liver Diseases
Suraj Patel, M.D., Ph.D., is an Assistant Professor of Internal Medicine and the Center for Human Nutrition at UT Southwestern Medical Center, and a member of the division of Digestive and Liver Diseases. His clinical interests include obesity, non-alcoholic fatty liver disease, and alcohol-related liver disease.
Originally from New Jersey, Dr. Patel holds a bachelor's degree in mechanical and aerospace engineering from Cornell University in Ithaca, New York, where he graduated magna cum laude. He then received master's and doctoral degrees in bioengineering and immunology from the Massachusetts Institute of Technology and Harvard Medical School in Cambridge, Massachusetts, before pursuing his medical degree at Rutgers University in New Brunswick, New Jersey. Dr. Patel then completed internal medicine residency training at UT Southwestern, before receiving advanced training through a fellowship program in gastroenterology at Massachusetts General Hospital in Boston, while simultaneously conducting a research fellowship in endocrinology, diabetes and metabolism at Beth Israel Deaconess Medical Center (BIDMC). Afterward, he remained at BIDMC to become a member of the clinical faculty.
Certified by the American Board of Internal Medicine, Dr. Patel joined the UT Southwestern faculty in 2021.
Dr. Patel focuses his research on the metabolic causes and consequences of liver disease, and how the immune system influences liver metabolism. He combines conventional biological methods with novel transcriptomic and epigenomic techniques to develop therapies that limit organ dysfunction and improve patient health in metabolic disease. His investigations have resulted in numerous publications in peer-reviewed journals, and he has been invited to present his findings throughout the United States and around the world.
Dr. Patel is an active member of several professional organizations, including the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterology Association. He also serves as an ad hoc reviewer for numerous scientific journals, including Hepatology, Digestive Diseases and Sciences, Therapeutic Advances in Gastroenterology, Human Immunology, Tissue Engineering, Technology, The New England Journal of Medicine, and the Journal of Hepatology.
Serum HMGB1 associates with liver disease and predicts readmission and mortality in patients with alcohol use disorder.
Vannier AGL, Wardwell B, Fomin V, PeBenito A, Wolczynski N, Piaker S, Kedrin D, Chung RT, Schaefer E, Goodman R, Patel SJ, Luther J, Alcohol (Fayetteville, N.Y.) 2021 09 95 37-43
Amphipathic peptide-based fusion peptides and immunoconjugates for the targeted ablation of prostate cancer cells.
Rege K, Patel SJ, Megeed Z, Yarmush ML, Cancer research 2007 Jul 67 13 6368-75
Gap junction inhibition prevents drug-induced liver toxicity and fulminant hepatic failure.
Patel SJ, Milwid JM, King KR, Bohr S, Iracheta-Vellve A, Iracheta-Velle A, Li M, Vitalo A, Parekkadan B, Jindal R, Yarmush ML, Nature biotechnology 2012 Jan 30 2 179-83
Hepatic connexin 32 associates with nonalcoholic fatty liver disease severity.
Luther J, Gala MK, Borren N, Masia R, Goodman RP, Moeller IH, DiGiacomo E, Ehrlich A, Warren A, Yarmush ML, Ananthakrishnan A, Corey K, Kaplan LM, Bhatia S, Chung RT, Patel SJ, Hepatology communications 2018 Jul 2 7 786-797
Hepatic gap junctions amplify alcohol liver injury by propagating cGAS-mediated IRF3 activation.
Luther J, Khan S, Gala MK, Kedrin D, Sridharan G, Goodman RP, Garber JJ, Masia R, Diagacomo E, Adams D, King KR, Piaker S, Reinecker HC, Yarmush ML, Argemi J, Bataller R, Dienstag JL, Chung RT, Patel SJ, Proceedings of the National Academy of Sciences of the United States of America 2020 05 117 21 11667-11673
DNA-triggered innate immune responses are propagated by gap junction communication.
Patel SJ, King KR, Casali M, Yarmush ML, Proceedings of the National Academy of Sciences of the United States of America 2009 Aug 106 31 12867-72
Hepatic Injury in Nonalcoholic Steatohepatitis Contributes to Altered Intestinal Permeability.
Luther J, Garber JJ, Khalili H, Dave M, Bale SS, Jindal R, Motola DL, Luther S, Bohr S, Jeoung SW, Deshpande V, Singh G, Turner JR, Yarmush ML, Chung RT, Patel SJ, Cellular and molecular gastroenterology and hepatology 2015 Mar 1 2 222-232
A Novel Resolvin-Based Strategy for Limiting Acetaminophen Hepatotoxicity.
Patel SJ, Luther J, Bohr S, Iracheta-Vellve A, Li M, King KR, Chung RT, Yarmush ML, Clinical and translational gastroenterology 2016 Mar 7 e153
Alternative erythropoietin-mediated signaling prevents secondary microvascular thrombosis and inflammation within cutaneous burns.
Bohr S, Patel SJ, Shen K, Vitalo AG, Brines M, Cerami A, Berthiaume F, Yarmush ML, Proceedings of the National Academy of Sciences of the United States of America 2013 Feb 110 9 3513-8
Early liver transplantation for alcoholic hepatitis: Ready for primetime?
Kubiliun M, Patel SJ, Hur C, Dienstag JL, Luther J, Journal of hepatology 2018 03 68 3 380-382
- Serum HMGB1 associates with liver disease and predicts readmission and mortality in patients with alcohol use disorder.